The RAS-RAF-MEK-ERK (RAS-ERK) signaling pathway is affected in many human cancers as a result of the abnormal activation of upstream receptor tyrosine kinases or gain-of-function mutations predominantly of the RAS or RAF genes [14,15]. This evidence concerns the gene MAP2K7 and cancer.